187 related articles for article (PubMed ID: 25331161)
1. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
3. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
Dispenzieri A; Gertz MA; Kumar SK; Lacy MQ; Kyle RA; Saenger AK; Grogan M; Zeldenrust SR; Hayman SR; Buadi F; Greipp PR; Leung N; Russell SR; Dingli D; Lust JA; Rajkumar SV; Jaffe AS
Heart; 2014 Mar; 100(5):383-8. PubMed ID: 24402772
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
5. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
7. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
8. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay.
Kristen AV; Giannitsis E; Lehrke S; Hegenbart U; Konstandin M; Lindenmaier D; Merkle C; Hardt S; Schnabel PA; Röcken C; Schonland SO; Ho AD; Dengler TJ; Katus HA
Blood; 2010 Oct; 116(14):2455-61. PubMed ID: 20581312
[TBL] [Abstract][Full Text] [Related]
9. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
Swiger KJ; Friedman EA; Brittain EL; Tomasek KA; Huang S; Su YR; Sawyer DB; Lenihan DJ
Amyloid; 2016 Dec; 23(4):242-248. PubMed ID: 27809600
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification in cardiac amyloidosis: novel approaches.
Kristen AV; Meyer FJ; Perz JB; Schonland SO; Hundemer M; Hegenbart U; Singer R; Schnabel PA; Sack FU; Goldschmidt H; Katus HA; Dengler TJ
Transplantation; 2005 Sep; 80(1 Suppl):S151-5. PubMed ID: 16286895
[TBL] [Abstract][Full Text] [Related]
12. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
[TBL] [Abstract][Full Text] [Related]
13. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
Jungbauer CG; Riedlinger J; Block D; Stadler S; Birner C; Buesing M; König W; Riegger G; Maier L; Luchner A
Biomark Med; 2014; 8(6):777-89. PubMed ID: 25224934
[TBL] [Abstract][Full Text] [Related]
14. The Interplay between Fasting Glucose, Echocardiography, and Biomarkers: Pathophysiological Considerations and Prognostic Implications.
Pareek M
Dan Med J; 2017 Sep; 64(9):. PubMed ID: 28874244
[TBL] [Abstract][Full Text] [Related]
15. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
16. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
17. LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis.
Boynton SJ; Geske JB; Dispenzieri A; Syed IS; Hanson TJ; Grogan M; Araoz PA
JACC Cardiovasc Imaging; 2016 Jun; 9(6):680-6. PubMed ID: 27209101
[TBL] [Abstract][Full Text] [Related]
18. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure.
Aimo A; Januzzi JL; Vergaro G; Ripoli A; Latini R; Masson S; Magnoli M; Anand IS; Cohn JN; Tavazzi L; Tognoni G; Gravning J; Ueland T; Nymo SH; Rocca HB; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Wilson Tang WH; Grodin JL; Passino C; Emdin M
Int J Cardiol; 2019 Feb; 277():166-172. PubMed ID: 30416028
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of placental growth factor in patients with acute chest pain.
Heeschen C; Dimmeler S; Fichtlscherer S; Hamm CW; Berger J; Simoons ML; Zeiher AM;
JAMA; 2004 Jan; 291(4):435-41. PubMed ID: 14747500
[TBL] [Abstract][Full Text] [Related]
20. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
